From: www.argentina.gob.ar
ANMAT published last week the "Disposición ANMAT Nº 3289/19", where is established the new procedures for Bioequivalence studies.
The new rule will be mandatory for all drugs containing Active Pharmaceutical Ingredients (API) that require bioequivalence studies according the local regulation; and also can be applied to all other APIs due to the companies interest.
